Hong Kong vs Poland: Life science patents granted, by technology
Hong Kong
54 patents
in 2020
Poland
68 patents
in 2023
Hong Kong rank
21st
Poland rank
19th
Life science patents granted, by technology over time
- Hong Kong
- Poland
How they compare
Poland currently reports 68 patents against 54 patents in Hong Kong, a difference of 14 patents.
That makes Poland's figure about 1.3 times Hong Kong's.
The two have swapped places 2 times across 21 shared years of data; in 1998 it was Poland ahead.
Hong Kong ranks 21st and Poland ranks 19th of 65 countries.
Poland has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Hong Kong | Poland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 1 patents | 131 patents | 130 patents | Poland |
| 2000s | 77.44 patents | 216.78 patents | 139.33 patents | Poland |
| 2010s | 10.7 patents | 148.3 patents | 137.6 patents | Poland |
| 2020s | 54 patents | 101 patents | 47 patents | Poland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Hong Kong or Poland?
- Poland, at 68 patents against 54 patents in Hong Kong as of 2023.
- What is the difference in life science patents granted, by technology between Hong Kong and Poland?
- 14 patents, with Poland ahead.
- How many years of comparable data are there for Hong Kong and Poland?
- 21 years are reported by both, from 1998 to 2020.
- How do Hong Kong and Poland rank globally for life science patents granted, by technology?
- Hong Kong ranks 21st and Poland ranks 19th of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.